Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + pioglitazone
- Development stage
- Phase 3
- Lead developer
- EMS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Piemonte association** is an investigational oral fixed-dose combination of **empagliflozin 25 mg** and **pioglitazone 30 mg** being developed by EMS for type 2 diabetes mellitus. Empagliflozin selectively inhibits sodium-glucose cotransporter 2 in the kidney, increasing urinary glucose excretion, while pioglitazone activates peroxisome proliferator-activated receptor gamma to improve insulin sensitivity and glucose utilization. The combination is being evaluated against each individual component in the randomized, double-blind, triple-dummy Phase 3 EMS1020 study, NCT05028140. ([cpclimmarilia.com.br](https://www.cpclimmarilia.com.br/estudo/piemonte))
- Other names
- empagliflozin + pioglitazonePiemontePiemonte association
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on empagliflozin + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + pioglitazone.